AFFLUENT MEDICAL SA (AFME.PA) Stock Price, Forecast & Analysis
Europe - EPA:AFME - FR0013333077 - Common Stock
AFME.PA Key Statistics, Chart & Performance
The current stock price of AFME.PA is 1.63 EUR. In the past month the price increased by 10.14%. In the past year, price decreased by -13.3%.
AFME.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1EL.MI | ESSILORLUXOTTICA | 46.26 | 147.19B | ||
| ESL.DE | ESSILORLUXOTTICA | 46.2 | 147.00B | ||
| EL.PA | ESSILORLUXOTTICA | 46.19 | 146.96B | ||
| 2U3.DE | ALCON INC | 25.03 | 32.64B | ||
| CBHD.DE | COLOPLAST-B | 30.7 | 16.45B | ||
| AFW.DE | ALIGN TECHNOLOGY INC | 14.62 | 8.87B | ||
| GENT.OL | GENTIAN DIAGNOSTICS ASA | 20.52 | 851.18M | ||
| GBT.PA | GUERBET | 26.1 | 201.23M | ||
| ALCJ.PA | CROSSJECT | N/A | 125.09M | ||
| SVS.MI | SVAS BIOSANA SPA | 7.72 | 54.88M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 38.19M | ||
| IVN.MI | IVISION TECH SPA | N/A | 17.32M |
Related stock screener links
About AFME.PA
Company Profile
Affluent Medical SA provides treatments for serious and widespread diseases. The company is headquartered in Aix-En-Provence, Paca and currently employs 69 full-time employees. The company went IPO on 2021-06-14. The company designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. The company provides several products such as Kalios, Epygon, Artus. The company helps in treating heart disease and urinary incontinence. The firm provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.
Company Info
AFFLUENT MEDICAL SA
320 avenue Archimede, Les pleiades III Batiment B
Aix-en-Provence PACA FR
Employees: 66
Phone: 33442951220
AFFLUENT MEDICAL SA / AFME.PA FAQ
What does AFFLUENT MEDICAL SA do?
Affluent Medical SA provides treatments for serious and widespread diseases. The company is headquartered in Aix-En-Provence, Paca and currently employs 69 full-time employees. The company went IPO on 2021-06-14. The company designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. The company provides several products such as Kalios, Epygon, Artus. The company helps in treating heart disease and urinary incontinence. The firm provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.
Can you provide the latest stock price for AFFLUENT MEDICAL SA?
The current stock price of AFME.PA is 1.63 EUR. The price increased by 6.54% in the last trading session.
What is the dividend status of AFFLUENT MEDICAL SA?
AFME.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of AFME stock?
AFME.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the sector and industry classification for AFFLUENT MEDICAL SA?
AFFLUENT MEDICAL SA (AFME.PA) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the market capitalization of AFME stock?
AFFLUENT MEDICAL SA (AFME.PA) has a market capitalization of 64.14M EUR. This makes AFME.PA a Micro Cap stock.
AFME.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to AFME.PA. When comparing the yearly performance of all stocks, AFME.PA turns out to be only a medium performer in the overall market: it outperformed 45.46% of all stocks.
AFME.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AFME.PA. AFME.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
AFME.PA Financial Highlights
Over the last trailing twelve months AFME.PA reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 29.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.64% | ||
| ROE | -69.84% | ||
| Debt/Equity | 1 |
AFME.PA Forecast & Estimates
10 analysts have analysed AFME.PA and the average price target is 3.72 EUR. This implies a price increase of 128.4% is expected in the next year compared to the current price of 1.63.